Introduction {#S1}
============

The purinergic agonist, adenosine 5′-triphosphate (ATP), is an important and ubiquitous extracellular signalling molecule that mediates diverse physiological effects in numerous cell types and is pivotal in regulating smooth muscle activity, ranging from gastrointestinal motility to vascular tone ([@R1]; [@R11]; [@R15]; [@R23]). Alterations in ATP signalling are implicated in several pathological conditions of smooth muscle, including inflammatory bowel disease, partial bladder outlet obstruction and hypertension ([@R11]; [@R13]; [@R61]) and there is an emerging role of purinergic receptors as therapeutic targets in such conditions. A major regulator of smooth muscle function is the cytoplasmic Ca^2+^ concentration \[Ca^2+^\]~c~ ([@R4]; [@R31]). Ca^2+^ release from the intracellular Ca^2+^ store, the sarcoplasmic reticulum (SR), provides a significant mechanism by which agonists such as ATP may regulate \[Ca^2+^\]~c~ and thus, smooth muscle activity. Release occurs via two ligand-gated channel--receptor complexes, the inositol 1,4,5-trisphosphate receptor \[Ins(1,4,5)*P*~3~R\] and the ryanodine receptor (RyR) ([@R7]; [@R56]). In several cell types, such as smooth muscle, Ins(1,4,5)*P*~3~R is the predominant Ca^2+^ release mechanism and is activated by Ins(1,4,5)*P*~3~, generated via G-protein- or tyrosine kinase-linked receptor-dependent activation of phospholipase C (PLC) ([@R7]; [@R33]; [@R48]).

Smooth muscle cells express ligand-gated P2X receptors (P2XR) and G-protein-coupled P2Y receptors (P2YR). Many of the physiological effects of neuronally released ATP in smooth muscle are influenced by the relaxant actions of P2YR ([@R1]; [@R12]; [@R23]; [@R38]), which are largely coupled to Gα~q~ proteins and thus to the activation of PLC. Indeed, the direct inhibitory response to ATP on smooth muscle has been proposed to involve PLC-mediated phosphoinositide hydrolysis and the subsequent ATP-dependent production of Ins(1,4,5)*P*~3~ to evoke local Ca^2+^ release near the plasma membrane via Ins(1,4,5)*P*~3~Rs. The \[Ca^2+^\]~c~ rise, it is proposed, may activate Ca^2+^-activated K^+^ (K~Ca~) channels to hyperpolarize the plasma membrane and decrease bulk average \[Ca^2+^\]~c~ ([@R2]; [@R10]; [@R23]; [@R39]; [@R75]; [@R78]). Yet, the frequency with which ATP-induced \[Ca^2+^\]~c~ rises are observed varies substantially. For example, a recent study reported that \[Ca^2+^\]~c~ rises to ATP were not observed in colonic smooth muscle cells ([@R40]) and in other preparations approximately one-third of cells failed to respond to ATP with a rise in \[Ca^2+^\]~c~ ([@R18]; [@R21]; [@R44]) or ATP-induced Ca^2+^ responses may be either limited or not observed at all ([@R3]; [@R22]; [@R37]; [@R65]). These observations suggest that activation of K~Ca~ channels, following Ca^2+^ store release, may not be a universal mechanism of P2YR-mediated signal transduction.

In the present investigation, the effect of ATP on Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release was initially examined to characterise the release of Ca^2+^ from the SR by ATP. Freshly isolated single colonic smooth muscle cells were selected, which provide a robust model for studying Ins(1,4,5)*P*~3~R activity. The use of flash photolysis of caged Ins(1,4,5)*P*~3~ minimised the activation of second messenger systems, to give a clearer understanding of the control of Ca^2+^ release via Ins(1,4,5)*P*~3~R. The study shows that ATP failed to evoke a rise in \[Ca^2+^\]~c~ in most cells, but instead inhibited Ins(1,4,5)*P*~3~-evoked Ca^2+^ release. This effect was dependent on G-protein-coupled P2Y~1~R activation, but independent of PLC. Thus we propose here, a novel mechanism by which ATP regulates Ins(1,4,5)*P*~3~-evoked Ca^2+^ release in smooth muscle.

Results {#S2}
=======

Initial experiments were designed to characterise the release of store Ca^2+^ by ATP. Unexpectedly, however, ATP (1 mM) transiently increased \[Ca^2+^\]~c~ (Δ*F*/*F*~0~=2.0±0.4) in only \~10% of single smooth muscle cells ([Fig. 1A](#F1){ref-type="fig"}, 9 of 87 cells) voltage-clamped at −70 mV, but did not evoke any resolvable current responses in these cells ([Fig. 1A](#F1){ref-type="fig"}). ATP failed to evoke Ca^2+^ release in the remaining cells ([Fig. 1B](#F1){ref-type="fig"}). The absence of a Ca^2+^ rise in response to ATP cannot be explained by clamping the cells at −70 mV since the agonist also failed to evoke Ca^2+^ release at −30 mV ([Fig. 1C](#F1){ref-type="fig"}, *n*=11).

ATP inhibits Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release {#S3}
------------------------------------------------------

We hypothesised that ATP may inhibit Ins(1,4,5)*P*~3~R-mediated Ca^2+^ signalling in cells that did not display an increase in \[Ca^2+^\]~c~ in response to purinergic stimulation. Therefore, the effect of ATP on Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release from the store was examined. In these experiments, the Ins(1,4,5)*P*~3~ generating agonist, carbachol (CCh), was applied in a Ca^2+^-free bath solution to prevent Ca^2+^ influx and record purely store Ca^2+^ release. CCh (100 μM) elicited reproducible transient \[Ca^2+^\]~c~ increases in single myocytes ([Fig. 2A](#F2){ref-type="fig"}) which is routinely observed in \~50% of cells. ATP (1 mM), applied 2 seconds before CCh, failed to release Ca^2+^ from the store, but significantly (*P*\<0.05) inhibited CCh-evoked \[Ca^2+^\]~c~ increases (Δ*F*/*F*~0~) by 76±7% (from 2.28±0.2 to 0.61±0.1, *n*=6, [Fig. 2A](#F2){ref-type="fig"}). Since ATP did not release Ca^2+^, neither activation of K~Ca~ channels nor depletion of the store of Ca^2+^ can explain these results. In fact, if the reduction in Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release arose by depletion of the store of Ca^2+^, then ATP would be expected to inhibit RyR-mediated Ca^2+^ release, because both Ins(1,4,5)*P*~3~R and RyR access a single common Ca^2+^ store in this smooth muscle preparation ([@R54]). Hence, SR Ca^2+^ release was evoked by the RyR activator, caffeine (10 mM), which reproducibly increased \[Ca^2+^\]~c~ ([Fig. 2B](#F2){ref-type="fig"}). ATP (1 mM), applied 2 seconds before caffeine, did not alter caffeine-evoked \[Ca^2+^\]~c~ increases \[(Δ*F*/*F*~0~) from 2.01±0.4 (control) compared with 2.04±0.3 (following ATP), *n*=4\]. Together, the results suggest that ATP inhibits Ins(1,4,5)*P*~3~R-mediated Ca^2+^ signalling.

The inhibition of CCh-evoked Ca^2+^ release by ATP may arise from either inhibition of Ins(1,4,5)*P*~3~ synthesis or alternatively, Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release. To distinguish between these possibilities, Ins(1,4,5)*P*~3~R were activated *directly* using caged Ins(1,4,5)*P*~3~ which obviates the synthesis of Ins(1,4,5)*P*~3~. In these experiments, photo release of caged Ins(1,4,5)*P*~3~ elicited reproducible transient \[Ca^2+^\]~c~ elevations in voltage-clamped single myocytes ([Fig. 2C](#F2){ref-type="fig"}). Again, ATP (1 mM), applied 2 seconds before Ins(1,4,5)*P*~3~, significantly (*P*\<0.05) decreased Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases (Δ*F*/*F*~0~) by 87±5% (from 1.17±0.04 to 0.15±0.01, *n*=5, [Fig. 2C](#F2){ref-type="fig"}). A similar inhibition was observed when ATP was applied at up to 10-fold lower concentrations. Since the \[Ca^2+^\]~c~ increase evoked by photolysis of caged Ins(1,4,5)*P*~3~ does not require Ins(1,4,5)*P*~3~ synthesis, these results suggest that ATP inhibited Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release.

ATP inhibits Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release via P2Y~1~R {#S4}
------------------------------------------------------------------

A structural analogue of ATP, adenosine 5′-diphosphate (ADP, 1 mM), also significantly decreased Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases (Δ*F*/*F*~0~) by 76±7% (from 1.76±0.3 to 0.40±0.1, *n*=3, *P*\<0.05, [Fig. 3A](#F3){ref-type="fig"}) indicating that the purinergic inhibitory response may be mediated by P2YR. Again, a similar inhibition was observed when ADP was applied at up to 10-fold lower concentrations. In contrast, adenosine (1 mM), applied 2 seconds before Ins(1,4,5)*P*~3~, did not however, alter Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ rises (Δ*F*/*F*~0~ from 1.95±0.2 to 2.02±0.2, *n*=4, [Fig. 3B](#F3){ref-type="fig"}), excluding a role for adenosine receptors. Consistent with these data, the inhibitory effect of ATP on Ins(1,4,5)*P*~3~-evoked Ca^2+^ release was blocked by the selective P2Y~1~R antagonist, MRS2179 ([@R8]). ATP (1 mM), applied 2 seconds before Ins(1,4,5)*P*~3~, significantly (*P*\<0.05) decreased Ins(1,4,5)*P*~3~-evoked Ca^2+^ release (Δ*F*/*F*~0~ from 1.12±0.04 to 0.38±0.09, *n*=5, [Fig. 4](#F4){ref-type="fig"}). The inhibitory response to ATP was abolished by MRS2179 (10 μM) (Δ*F*/*F*~0~ 1.17±0.04, *n*=5, P\>0.05 compared to control, [Fig. 4](#F4){ref-type="fig"}), confirming a role of P2Y~1~R in this response.

Role of G proteins in ATP-evoked inhibition of Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release {#S5}
----------------------------------------------------------------------------------------

Although P2Y~1~R classically couple to Gα~q/11~ G proteins ([@R1]), agonist stimulation of P2Y~1~R can lead, in some instances, to physiological responses that are independent of G protein activation ([@R19]; [@R28]; [@R42]; [@R63]). The potential role of G proteins in the ATP-mediated inhibition of Ins(1,4,5)*P*~3~-evoked Ca^2+^ release was therefore, examined using the membrane-impermeable G protein inhibitor, GDP 5′-O-(2-thio-diphosphate) (GDPβS), introduced into the cell via the patch electrode ([Fig. 5](#F5){ref-type="fig"}). GDPβS (10 μM) abolished the inhibitory effect of ATP on Ins(1,4,5)*P*~3~-evoked Ca^2+^ release \[Δ*F*/*F*~0~ from 1.79±0.1 (control) compared with 1.85±0.1 (following ATP), *n*=8\], indicating that the inhibitory response to ATP requires G protein activation.

ATP-evoked inhibition of Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release does not require PLC {#S6}
---------------------------------------------------------------------------------------

G-protein-coupled P2YR-mediated effects are mainly mediated by activation of PLC ([@R1]). Thus, to investigate the role of PLC in mediating the ATP-dependent inhibition of Ins(1,4,5)*P*~3~-evoked Ca^2+^ release, we examined the effects of the PLC inhibitor, edelfosine. ATP (1 mM), applied 2 seconds before Ins(1,4,5)*P*~3~, significantly (*P*\<0.05) decreased Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases (Δ*F*/*F*~0~ from 2±0.39 to 0.14±0.01, *n*=4, [Fig. 6A](#F6){ref-type="fig"}) and remained effective in decreasing Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ rises in the presence of the PLC inhibitor, edelfosine (10 μM) (Δ*F*/*F*~0~ from 2±0.39 to 0.17±0.01, *n*=4, *P*\<0.05, [Fig. 6A](#F6){ref-type="fig"}). On the other hand, edelfosine significantly inhibited Ca^2+^ release evoked by the Ins(1,4,5)*P*~3~ generating agonist, CCh, (Δ*F*/*F*~0~) by 93±2% (from 1.88±0.3 to 0.12±0.03, *n*=6, *P*\<0.05; [Fig. 6B](#F6){ref-type="fig"}), a result that is consistent with the proposed mechanism of action of the drug ([@R69]).

Having previously demonstrated that the commonly used PLC inhibitor, U-73122, exerts non-selective effects on SR Ca^2+^ pumps in this tissue ([@R46]), it was necessary to confirm the selectivity of edelfosine as a PLC inhibitor. Edelfosine affected neither Ins(1,4,5)*P*~3~- \[Δ*F*/*F*~0~ from 1.70±0.3 (control) to 1.73±0.3 (edelfosine), *n*=4, [Fig. 7A](#F7){ref-type="fig"}\] or RyR- \[Δ*F*/*F*~0~ from 2.84±0.1 (control) to 3.06±0.2 (edelfosine), *n*=4, [Fig. 7B](#F7){ref-type="fig"}\] evoked Ca^2+^ release nor the rate of Ca^2+^ removal from the cytoplasm following release. The 80--20% decay interval following Ins(1,4,5)*P*~3~- and caffeine-evoked Ca^2+^ release was 3.1±0.4 s and 3.6±0.5 s in controls and 3.2±0.5 s and 3.4±0.5 s in edelfosine (*n*=4 and 4), respectively.

In conclusion, these results suggest that P2Y~1~R inhibition of Ins(1,4,5)*P*~3~-evoked Ca^2+^ release is G-protein dependent. A product of the PLC-mediated signalling pathway is not responsible for ATP-dependent inhibition of Ca^2+^ release.

Discussion {#S7}
==========

At present the mechanism by which ATP mediates smooth muscle relaxation is contentious. The present study demonstrates that ATP induced Ca^2+^ release in only a minority of smooth muscle cells. Instead, in cells that did not show a \[Ca^2+^\]~c~ rise in response to purinergic stimulation, ATP inhibited Ins(1,4,5)*P*~3~-evoked Ca^2+^ release. This response was mediated by P2Y~1~R and was G protein dependent, but did not involve activation of PLC. Thus we propose a novel mechanism for smooth muscle relaxation whereby stimulation of a G-protein-coupled receptor inhibits Ins(1,4,5)*P*~3~-evoked Ca^2+^ release to promote relaxation.

Our initial experiments found that ATP increased \[Ca^2+^\]~c~ in only \~10% of voltage-clamped single smooth muscle cells. The absence of an increase in \[Ca^2+^\]~c~ in response to ATP was not influenced by changes in membrane potential and so, cannot be accounted for by voltage control of Ins(1,4,5)*P*~3~ production or Ins(1,4,5)*P*~3~-dependent Ca^2+^ release ([@R5]; [@R25]; [@R34]; [@R47]; [@R49]; [@R50]). This is intriguing because it is generally believed that purinergic activation leads to the mobilization of Ins(1,4,5)*P*~3~-sensitive Ca^2+^ stores and hyperpolarization of smooth muscle ([@R23]; [@R29]; [@R39]; [@R41]; [@R75]; [@R76]; [@R78]). Evidently, a requirement for this mechanism is Ca^2+^ release from the internal store. However, recent evidence from another group, although having previously been in support of this model, also suggest that ATP failed to elicit increased responses in isolated smooth muscle cells ([@R40]), while the relatively small purinergic K~Ca~ current evoked by ATP or the inability to elicit K~Ca~ currents in smooth muscle ([@R40]) is inconsistent with previous studies supporting the concept of purinergic signalling via intracellular Ca^2+^ release and subsequent activation of K~Ca~ channels in smooth muscle. Thus, it appears that only a sub-population of smooth muscle cells may be organised to hyperpolarize in response to ATP.

Our results provide an additional mechanism by which ATP may evoke smooth muscle relaxation, that is by modulation of Ins(1,4,5)*P*~3~R-mediated Ca^2+^ signalling. ATP suppressed \[Ca^2+^\]~c~ increases evoked by CCh (Ins(1,4,5)*P*~3~ generating agonist) and by photolysis of a caged form of the inositide, to release Ins(1,4,5)*P*~3~, in all cells that failed to respond to purinergic activation with an increase in \[Ca^2+^\]~c~. Since ATP did not evoke Ca^2+^ release from the store, neither K~Ca~ channel activation nor Ca^2+^ store depletion can explain the inhibitory response to ATP. Neither can the inhibitory response to ATP be attributed to inhibition of Ins(1,4,5)*P*~3~ synthesis since Ins(1,4,5)*P*~3~ was released by photolysis and so synthesis was not required. Consistent with our data, ATP exerted an inhibitory effect on muscarinic-mediated increases in intracellular Ca^2+^ release in platelets and acinar cells ([@R22]; [@R32]; [@R35]; [@R57]; [@R74]). These studies also concluded that the mechanism underlying the ATP-dependent inhibition of Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release appears to extend beyond the plasma membrane, but is not due to depletion of the store. ATP, at a concentration which fully inhibits Ca^2+^ store release, affected neither the interaction of agonists with their respective cell surface receptors nor Ca^2+^ store content ([@R32]; [@R35]).

In the present study the ATP-mediated inhibitory response was mimicked by ADP and blocked by the P2Y~1~R antagonist, MRS2179, in accordance with previous studies which demonstrate that ATP mediates its relaxant actions through the activation of P2Y~1~R ([@R9]; [@R23]; [@R24]; [@R51]). Furthermore, ATP was not being hydrolysed to adenosine by ectonucleotidases ([@R26]; [@R36]; [@R43]; [@R58]), as demonstrated by the lack of effect of the nucleoside on Ins(1,4,5)*P*~3~-evoked Ca^2+^ release. The inability of ATP to elicit inward currents in these cells also excludes a role of P2XR. Thus, it appears that the inhibitory response to ATP may be ascribed to the inhibition of Ins(1,4,5)*P*~3~-evoked Ca^2+^ release via P2Y~1~R activation.

The inhibitory effects of ATP in these experiments were abolished by the G protein inhibitor, GDPβS, indicating that activation of P2Y~1~R led to downstream stimulation of G proteins. This is important as in some cases P2Y~1~R stimulation can evoke responses that are G protein independent ([@R19]; [@R28]; [@R42]; [@R63]). However, P2Y~1~R characteristically couple to the Gα~q/11~ G proteins ([@R1]), which in turn stimulate PLC. Thus, we focused on a role of PLC in this inhibition. However, the actions of ATP were unaffected by the PLC inhibitor, edelfosine, at a concentration that inhibited CCh-evoked \[Ca^2+^\]~c~ increases. This is consistent with our conclusion that ATP did not act by inhibiting Ins(1,4,5)*P*~3~ synthesis, as has been proposed in glandular cells ([@R35]; [@R57]). We have also demonstrated that the PLC inhibitor used in the former study to confirm a contribution of PLC attenuates Ins(1,4,5)*P*~3~-evoked Ca^2+^ release by depleting the store of Ca^2+^, a mechanism unrelated to inhibition of PLC activity ([@R46]).

A likely candidate is activation of the cAMP second messenger pathway since P2Y~1~R can couple to cAMP pathways in addition to phosphoinositide pathways ([@R16]). However, studies carried out previously by us ([@R20]) have demonstrated that cAMP does not regulate Ins(1,4,5)*P*~3~R activity in these cells. Elevation of intracellular cAMP levels by either forskolin (which stimulates adenylate cyclase) or IBMX (which inhibits phosphodiesterase) did not significantly affect Ins(1,4,5)*P*~3~-evoked Ca^2+^ release. We also examined the involvement of kinase activation, since Ins(1,4,5)*P*~3~R can be greatly affected by phosphorylation. However, Ins(1,4,5)*P*~3~-evoked Ca^2+^ release was not altered by the broad spectrum kinase inhibitor, H7 (100 μM; data not shown), and ATP remained effective in decreasing Ins(1,4,5)*P*~3~-evoked Ca^2+^ release in the presence of the broad spectrum PI3K (phosphoinositide 3-kinase) inhibitor, wortmannin (10 μM; data not shown), which is consistent with our previous work confirming that neither kinase (i.e. PKA, PKG and PKC) inhibition nor activation modulated Ins(1,4,5)*P*~3~-mediated Ca^2+^ release ([@R55]; [@R56]).

The intracellular signalling cascade downstream of G protein receptor-coupled (GPRC) activation clearly exhibits greater diversity than previously appreciated. Purinergic signalling is further complicated by the fact that P2Y~1~R may couple directly to more than one G protein isoform ([@R30]; [@R67]; [@R72]) and each G protein isoform may also activate multiple signalling pathways ([@R52]; [@R66]), resulting in a wide range of cellular responses ([@R6]; [@R14]; [@R59]; [@R60]; [@R70]). This may also be influenced by the physical proximity of the P2Y~1~R and its signalling components, which can be partitioned into specialised membrane microdomains. For example, GPCR ([@R62]), G proteins ([@R64]) and G protein effector enzymes ([@R66]) localise to these structures. Moreover, membrane organisation may be critically important for ATP to release store Ca^2+^ in a subpopulation of cells, despite being a potent inhibitor of Ins(1,4,5)*P*~3~R-mediated Ca^2+^ release. Thus, the microenvironment may permit selective cellular responses ([@R17]; [@R27]; [@R73]; [@R77]) by providing a mechanism for achieving specificity of the receptor-mediated Ins(1,4,5)*P*~3~ pathway.

The complexity of purinergic signalling pathways constitute a formidable obstacle to the complete understanding of the molecular mechanism of this inhibition. Equally perplexing is the very rapid speed of onset of the inhibition of Ca^2+^ release (i.e. 2 seconds) which likely excludes signalling through slower second messenger systems. We speculate that a such a rapid time course of inhibition may more likely be explained by the modulation of proteins which interact directly with the Ins(1,4,5)*P*~3~R such as IRBIT \[Ins(1,4,5)*P*~3~R binding protein released with Ins(1,4,5)*P*~3~\] or Ca^2+^ binding proteins (CaBP), and which can inhibit the Ca^2+^ release activity of the Ins(1,4,5)*P*~3~R channel. Further studies are necessary to characterise the precise molecular mechanism underlying inhibition of Ins(1,4,5)*P*~3~R activity by ATP, but may prove challenging.

In conclusion, purinergic relaxation of smooth muscle has largely been attributed to the mobilization of Ins(1,4,5)*P*~3~-sensitive Ca^2+^ stores to hyperpolarize the cell, but we propose quite the reverse, that P2Y~1~R activation at the plasma membrane inhibits direct activation of Ins(1,4,5)*P*~3~R in the SR by Ins(1,4,5)*P*~3~ to inhibit smooth muscle activity. Smooth muscle may be under dual, inhibitory control by purinergic nerves. Thus, we report here for the first time that ATP can regulate the mobilization of Ins(1,4,5)*P*~3~-sensitive Ca^2+^ stores by two diametrically opposed mechanisms which are mediated by the same receptor. Although the biological significance of this divergence in ATP signalling is not yet clear, it is tempting to speculate that this novel mode of regulation may reflect complementary mechanisms of smooth muscle relaxation which have developed to acquire the ability of coordinated contraction and relaxation under a variety of circumstances and in response to a variety of stimuli. The existence of multiple regulatory mechanisms represents an advantageous strategy that allows impairment of one or more of its components. It is therefore understandable that several complementary and cooperating mechanisms are in place to control smooth muscle relaxation. Nevertheless, this study highlights the differential ability of ATP to regulate Ins(1,4,5)*P*~3~R-mediated mobilization of intracellular Ca^2+^ which may provide the molecular basis for such heterogeneous responses to ATP which are recognised in a variety of cells.

Materials and Methods {#S8}
=====================

Cell isolation {#S9}
--------------

All animal care and experimental procedures complied with the Animal (Scientific Procedures) Act UK 1986. Male guinea pigs (500--700 g) were sacrificed by cervical dislocation and immediate exsanguination. A segment of distal colon was immediately removed and transferred to an oxygenated (95% O~2~, 5% CO~2~) physiological saline solution of the following composition (mM): NaCl 118.4, NaHCO~3~ 25, KCl 4.7, NaH~2~PO~4~ 1.13, MgCl~2~ 1.3, CaCl~2~ 2.7 and glucose 11 (pH 7.4). Following the removal of the mucosa from this tissue, single smooth muscle cells, from circular muscle, were isolated using a two-step enzymatic dissociation protocol ([@R53]), stored at 4°C and used the same day. All experiments and loading of cells with fluorescent dyes were conducted at room temperature (20±2°C).

Electrophysiological experiments {#S10}
--------------------------------

Cells were voltage clamped using conventional tight seal whole-cell recording ([@R46]; [@R71]). The composition of the extracellular solution was (mM): Na glutamate 80, NaCl 40, tetraethylammonium chloride 20, MgCl~2~ 1.1, CaCl~2~ 3, HEPES 10 and glucose 30 (pH 7.4 adjusted with NaOH 1 M). The Ca^2+^-free extracellular solution additionally contained (mM): MgCl~2~, 3 (substituted for Ca^2+^); and EGTA, 1. The pipette solution contained (mM): Cs~2~SO~4~ 85, CsCl 20, MgCl~2~ 1, HEPES 30, pyruvic acid 2.5, malic acid 2.5, KH~2~PO~4~ 1, MgATP 3, creatine phosphate 5, guanosine triphosphate 0.5, fluo-3 penta-ammonium salt 0.1 and caged Ins(1,4,5)*P*~3~-trisodium salt 0.025 (pH 7.2 adjusted with CsOH 1 M). Whole cell currents were amplified by an Axopatch amplifier (Axon instruments, Union City, CA, USA), low pass filtered at 500 Hz (8-pole bessel filter; Frequency Devices, Haverhill, MA, USA), and digitally sampled at 1.5 kHz using a Digidata interface, pCLAMP software (version 6.0.1, Axon Instruments) and stored on a personal computer for analysis.

\[Ca^2+^\]~c~ measurement {#S11}
-------------------------

\[Ca^2+^\]~c~ was measured as fluorescence using either the membrane-impermeable dye fluo-3 (penta-ammonium salt), introduced into the cell via the patch pipette ([@R45]), or the membrane-permeable dye, fluo-3 acetoxymethylester (AM) ([@R56]; [@R71]). Where \[Ca^2+^\]~c~ measurements were made using the AM dye, cells were loaded with fluo-3 AM (10 μM) in the presence of wortmannin (10 μM; to prevent contraction) for 30 minutes prior to the beginning of the experiment (*n*=10). Fluorescence was quantified using a microfluorimeter which consisted of an inverted microscope (Nikon, Surrey, UK) and a photomultiplier tube with a bi-alkali photo cathode. Fluo-3 was excited at 488 nm (bandpass 9 nm) by a PTI Delta Scan (Photon Technology International Inc., London, UK) through the epi-illumination port of the microscope (using one arm of a bifurcated quartz fibre optic bundle). Excitation light was passed through a field stop diaphragm to reduce background fluorescence and reflected off a 505 nm long-pass dichroic mirror. Emitted light was guided through a 535 nm barrier filter (bandpass 35 nm) to a photomultiplier in photon counting mode (Photon Technology International Inc., London, UK). Interference filters and dichroic mirrors were obtained from Glen Spectra (London, UK).

Caged Ins(1,4,5)*P*~3~ was photolysed to the uncaged compound by ultraviolet light, which was selected by passing the output of a xenon flash lamp (Rapp Optoelektronik, Hamburg, Germany) through a UG-5 filter to select UV light and merging into the excitation light path of the microfluorimeter using a quartz bifurcated fibre optic bundle. The nominal flash lamp energy was 57 mJ, measured at the output of the fibre optic bundle and the flash duration was \~1 ms.

Statistical analysis {#S12}
--------------------

Changes in \[Ca^2+^\]~c~ were expressed as the ratio (*F*/*F*~0~) of fluorescence counts (*F*) relative to baseline (control) values (taken as 1) before stimulation (*F*~0~). Summarised data are expressed as mean ± s.e.m. for *n* cells. Student's paired *t*-tests were applied to test and control conditions; a value of *P*\<0.05 was considered significant.

Materials {#S13}
---------

Caged Ins(1,4,5)*P*~3~-trisodium salt and fluo-3 AM were each purchased from Invitrogen (Paisley, UK). Fluo-3 penta-ammonium salt was purchased from TEF labs (Austin, Texas, USA). Edelfosine and MRS2179 were purchased from Tocris Bioscience (Bristol, UK). Papain and collagenase were purchased from Worthington Biochemical Corporation (Lakewood, NJ, USA). All other reagents were purchased from Sigma (Poole, Dorset, UK). Ins(1,4,5)*P*~3~ was released from its caged compound by flash photolysis. ATP (100 μM--1 mM), ADP (100 μM--1 mM), adenosine (1 mM), carbachol (100--250 μM) and caffeine (10 mM) were each applied by hydrostatic pressure ejection using a pneumatic pump (PicoPump PV 820, World Precision Instruments, Stevenage, Herts, UK). With pressure ejection, the concentration of the ejected drug at the cell is unknown, but will be significantly lower than that in the pipette owing to dilution in the bathing solution. Possible ejection artefacts were excluded by pressure ejection of the vehicle solution alone. The concentration of GDPβS and caged, non-photolysed Ins(1,4,5)*P*~3~ refers to that in the pipette. ATP, ADP, adenosine, carbachol and caffeine were each dissolved in extracellular bathing solution. Edelfosine was dissolved in water and GDPβS was dissolved in pipette solution. MRS2179 was dissolved in DMSO (final bath concentration of the solvent, 0.05%, was by itself ineffective). MRS2179 (10 μM) and edelfosine (10 μM) were each perfused into the solution bathing the cells (\~5 ml per min).
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![ATP evoked \[Ca^2+^\]~c~ rises in only a minority of single voltage-clamped myocytes.\
(**A,B**) ATP (1 mM by pressure ejection; ii) evoked transient \[Ca^2+^\]~c~ increases in only \~10% of cells voltage-clamped at --70 mV (iii) as indicated by *F*/*F*~0~ (Ai) and did not elicit any discernible current responses in these cells (iv). ATP failed to evoke Ca^2+^ release in the remaining cells (Bi). (**C**) Although photolysed caged Ins(1,4,5)*P*~3~ (▲) increased \[Ca^2+^\]~c~ (i), ATP (1 mM by pressure ejection; ii), however, failed to evoke \[Ca^2+^\]~c~ rises as indicated by *F*/*F*~0~ (i) in cells voltage clamped at --30 mV (iii).](emss-73875-f001){#F1}

![ATP inhibited Ins(1,4,5)*P*~3~R- but not RyR-mediated \[Ca^2+^\]~c~ increases in voltage-clamped single myocytes.\
(**A**) The Ins(1,4,5)*P*~3~-generating agonist, CCh (100--250 µM by pressure ejection; ii), increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. CCh was applied in a Ca^2+^-free bath solution to ensure that \[Ca^2+^\]~c~ rises arose by Ca^2+^ release from the SR. ATP (1 mM), applied by pressure ejection 2 s before CCh (iii), decreased CCh-evoked \[Ca^2+^\]~c~ increases. (**B**) Ca^2+^ release was evoked using the RyR activator, caffeine. Caffeine (CAF, 10 mM by pressure ejection; ii) increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. ATP (1 mM), applied by pressure ejection 2 s before caffeine (iii), did not alter caffeine-evoked \[Ca^2+^\]~c~ increases. (**C**) Photo release of caged Ins(1,4,5)*P*~3~ (▲), which activated Ins(1,4,5)*P*~3~R directly, increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. ATP (1 mM), applied by pressure ejection 2 s before Ins(1,4,5)*P*~3~ (ii), decreased Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases (*V*~M~ −70 mV).](emss-73875-f002){#F2}

![The inhibitory effect of ATP on Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases was mimicked by ADP, but not by adenosine in voltage-clamped single myocytes.\
At --70 mV photolysed caged Ins(1,4,5)*P*~3~ (▲) increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. ADP (1 mM; **A**) and adenosine (1 mM; **B**) were each applied by pressure ejection 2 s before Ins(1,4,5)*P*~3~ (ii). ADP decreased, whereas adenosine did not alter Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases.](emss-73875-f003){#F3}

![The inhibitory response to ATP was blocked by the P2Y~1~R antagonist, MRS2179, in voltage-clamped single myocytes.\
At --70 mV photolysed caged Ins(1,4,5)*P*~3~ (▲) increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. ATP (1 mM), applied by pressure ejection 2 s before Ins(1,4,5)*P*~3~ (ii), decreased Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases. The inhibitory effect of ATP on Ins(1,4,5)*P*~3~-evoked Ca^2+^ release was blocked by MRS2179 (10 μM).MRS2179 was perfused into the solution bathing the cells.](emss-73875-f004){#F4}

![The G protein inhibitor, GDPβS, blocked the inhibitory effect of ATP on Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases in voltage-clamped single myocytes.\
Photolysed caged Ins(1,4,5)*P*~3~ (▲) increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. GDPβS (1 mM, introduced via the patch pipette; pretreated for 7--15 mins) blocked the inhibitory effect of ATP (1 mM by pressure ejection, applied 2 s before Ins(1,4,5)*P*~3~; ii) on Ins(1,4,5)*P*~3~-evoked Ca^2+^ release (*V*~M~ --70 mV).](emss-73875-f005){#F5}

![The PLC inhibitor, edelfosine, did not alter the ATP-mediated reduction in Ins(1,4,5)*P*~3~-evoked Ca^2+^ release in voltage-clamped single myocytes.\
(**A**) Photolysed caged Ins(1,4,5)*P*~3~ (▲) increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. ATP (1 mM by pressure ejection, applied 2 s before Ins(1,4,5)*P*~3~; ii) decreased Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases. Edelfosine (10 μM, *n*=4) did not alter the inhibitory effect of ATP on Ins(1,4,5)*P*~3~-evoked Ca^2+^ release (*V*~M~ --70 mV). (**B**) The Ins(1,4,5)*P*~3~-generating agonist, CCh (100--250 μM by pressure ejection; ii), increased \[Ca^2+^\]~c~ (i) as indicated by *F*/*F*~0~. Edelfosine (10 μM) decreased CCh-evoked \[Ca^2+^\]~c~ increases (i), which is consistent with the proposed mechanism of action of the drug. Edelfosine was perfused into the solution bathing the cells.](emss-73875-f006){#F6}

![The PLC inhibitor, edelfosine, neither altered Ins(1,4,5)*P*~3~R- nor RyR-mediated \[Ca^2+^\]~c~ increases in voltage-clamped single myocytes.\
Photolysed caged Ins(1,4,5)*P*~3~ (▲; **A**) and the RyR activator, caffeine (CAF, 10 mM by pressure ejection; **B**ii), each increased \[Ca^2+^\]~c~ as indicated by *F*/*F*~0~. Edelfosine (10 μM) neither altered Ins(1,4,5)*P*~3~-evoked \[Ca^2+^\]~c~ increases (A) nor caffeine-evoked \[Ca^2+^\]~c~ increases (Bi; *V*~M~ --70 mV). Edelfosine was perfused into the solution bathing the cells.](emss-73875-f007){#F7}
